Evoke Pharma Company Profile (NASDAQ:EVOK)

Analyst Ratings

Consensus Ratings for Evoke Pharma (NASDAQ:EVOK) (?)
Ratings Breakdown: 1 Sell Rating(s), 4 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $14.43 (785.19% upside)

Analysts' Ratings History for Evoke Pharma (NASDAQ:EVOK)
Show:
DateFirmActionRatingPrice TargetActions
7/19/2016FBR & CoBoost Price TargetOutperform$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016Noble FinancialDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016Northland SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016Feltl & Co.DowngradeStrong-Buy -> SellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016Rodman & RenshawDowngradeBuy -> Neutral$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Ascendiant Capital MarketsBoost Price TargetBuy$11.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/1/2015HC WainwrightInitiated CoverageBuy$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2015Cantor FitzgeraldReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2014MLV & Co.Boost Price TargetBuy$12.50 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Evoke Pharma (NASDAQ:EVOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/11/2016Q116($0.41)($0.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.45)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.54)($0.42)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.60)($0.52)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.55)($0.58)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414($0.68)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.78)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014($0.73)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.36)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2014Q413($0.16)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q3 13($0.10)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Evoke Pharma (NASDAQ:EVOK)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.48)($0.37)($0.43)
Q2 20162($0.47)($0.47)($0.47)
Q3 20162($0.46)($0.37)($0.42)
Q4 20162($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Evoke Pharma (NASDAQ:EVOK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Evoke Pharma (NASDAQ:EVOK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/26/2016Parters Vii L P DomainMajor ShareholderSell344,120$4.70$1,617,364.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2016Parters Vii L P DomainMajor ShareholderSell5,095$5.07$25,831.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016Parters Vii L P DomainMajor ShareholderSell1,492$5.20$7,758.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Parters Vii L P DomainMajor ShareholderSell41,478$5.35$221,907.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2016Parters Vii L P DomainMajor ShareholderSell4,348$5.22$22,696.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2016Parters Vii L P DomainMajor ShareholderSell51,004$5.28$269,301.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Parters Vii L P DomainMajor ShareholderSell11,836$7.02$83,088.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2015Parters Vii L P DomainMajor ShareholderSell50,163$7.29$365,688.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014Todd C BradyDirectorBuy4,000$5.70$22,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Evoke Pharma (NASDAQ:EVOK)
DateHeadline
07/26/16 06:02 AMStock's Ratings to Focus: Eli Lilly and Company (NYSE:LLY) , Evoke Pharma, Inc. (NASDAQ:EVOK) - Street Updates
07/26/16 06:02 AMBrean Capital Downgrades Evoke Pharma Inc to Hold – Trade Calls - Trade Calls
07/25/16 03:56 PMFBR Capital reported on (NASDAQ:EVOK) Evoke Pharma, dropping its stock price target to $9 today
07/25/16 08:50 AMImportance Of Phase III Trials -
07/25/16 08:35 AMHot Stocks: Evoke Pharma, Inc. (NASDAQ:EVOK), Deluxe Corp. (NYSE:DLX), Groupon, Inc. (NASDAQ:GRPN), CRA ... - KC Register
07/23/16 03:47 PMIs $9 Price Target Attainable For Evoke Pharma, Inc. (NASDAQ:EVOK)? - Investor Newswire
07/22/16 03:50 PMBad Phase 3 Results Bring Evoke Pharma Inc (NASDAQ:EVOK) Down To The Ground
07/22/16 05:49 AMAnalysis under consideration: Evoke Pharma, Inc. (NASDAQ:EVOK) - News Oracle
07/22/16 05:49 AMHealthcare Stocks Try to Roars Again- Evoke Pharma, Inc. (NASDAQ:EVOK), CytRx Corporation (NASDAQ:CYTR) - Seneca Globe
07/21/16 04:03 PMFBR & Co Lowers Evoke Pharma Inc. (EVOK) Price Target to $9.00
07/21/16 07:27 AMEvoke Pharma, Inc. (NASDAQ:EVOK) plummeted -14.53%: Ryerson Holding Corporation (NYSE:RYI), Acorn ... - KC Register
07/21/16 07:27 AMOverview of Analyst's Recommendations: Evoke Pharma, Inc. (NASDAQ:EVOK) , Geron Corporation (NASDAQ:GERN) - Street Updates
07/20/16 05:12 PMDowngrades Evoke Pharma Inc. (EVOK) to Sell
07/20/16 05:12 PMEvoke Pharma (EVOK) Enters $4.5M Registered At-The-Market Stock Offering
07/20/16 03:04 PM2 Staggering Biotechs Join Wednesday’s 52-Week Low Club -
07/20/16 06:55 AMEVOKE PHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial -
07/20/16 06:30 AMEvoke Pharma Announces $4.5 Million At-The-Market Offering - [GlobeNewswire] - SOLANA BEACH, Calif., July 20, 2016-- Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has entered into definitive agreements ...
07/20/16 05:46 AMStock Focus: Following Analyst Expectations on Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) - TGP
07/19/16 09:11 PMHeightened Volatility Spotted on Shares of: Evoke Pharma, Inc. (NASDAQ:EVOK) - Engelwood Daily
07/19/16 09:11 PMTrading Action Review: Watching Unusual Volume on Evoke Pharma, Inc. (NASDAQ:EVOK) - Engelwood Daily
07/19/16 09:11 PMLosers Jumps in Healthcare Valley- Brainstorm Cell Therapeutics (NASDAQ:BCLI), Evoke Pharma (NASDAQ:EVOK) - Seneca Globe
07/19/16 09:11 PMAnalysts Observing Stocks Update: Evoke Pharma, Inc. (NASDAQ:EVOK) , Novo Nordisk A/S (NYSE:NVO) - Street Updates
07/19/16 09:11 PMEvoke Pharma Inc. (EVOK) Sank To A 5-Month Low After Phase 3 Study Failed - RTT News
07/19/16 04:02 PMEvoke Pharma Inc. (EVOK) Sank To A 5-Month Low After Phase 3 Study Failed
07/19/16 04:02 PMEvoke Pharma's Stock Sinks on Stomach Drug's Phase 3 Failure
07/19/16 10:01 AMTrader's Buzzers: KeyCorp. (KEY), Evoke Pharma, Inc. (EVOK), QUALCOMM Incorporated (QCOM) - iStreetWire
07/19/16 10:01 AMNext Weeks Broker Price Targets For Evoke Pharma, Inc. (EVOK) - Fiscal Standard
07/19/16 10:01 AMHot Line At Active Movers- Evoke Pharma (NASDAQ:EVOK), Tempur Sealy International. (NYSE:TPX), Sagent ... - Seneca Globe
07/19/16 10:01 AMRating Roundup: Evoke Pharma Inc (NASDAQ:EVOK) - Post Registrar
07/19/16 08:08 AMEvoke (EVOK) Stock Down on Poor Phase III EVK-001 Data -
07/19/16 07:49 AMEvoke Pharma downgraded by Noble Financial -
07/18/16 04:05 PMInvestor Watch: Volatility Recap on Shares of: Evoke Pharma, Inc. (NASDAQ:EVOK) - Engelwood Daily
07/18/16 04:05 PMHow Many Evoke Pharma Inc (NASDAQ:EVOK)'s Analysts Are Bearish? - Consumer Eagle
07/18/16 04:05 PMStock Declining in Trading Session: Evoke Pharma, Inc. (NASDAQ:EVOK) - TGP
07/18/16 04:05 PMEvoke Pharma Inc. (EVOK) Is Plunging After Phase 3 Study Failed - RTT News
07/18/16 04:05 PMBRIEF-Evoke Pharma reports results from EVK-001 Phase 3 clinical trial - Reuters
07/18/16 04:05 PMMid-Afternoon Market Update: Evoke Pharma Drops On Failed Phase 3 EVK-001 Data; ParkerVision Shares Spike ... - Benzinga
07/18/16 04:05 PMEvoke Pharma Inc (EVOK) Stock Crashes as Phase 3 Study of EVK-001 Misses Endpoint - Bidness ETC
07/18/16 04:05 PMEvoke Pharma stock drops 76% after drug's late-stage topline results miss primary endpoint - MarketWatch
07/18/16 03:38 PMTale Of The Technicals: Notable Price Action In Apple, Evoke And Microsoft -
07/18/16 03:04 PMCVR, CVR Refining in Monday’s 52-Week Low Club -
07/18/16 09:03 AMEvoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial
07/18/16 09:03 AMEvoke Pharma: EVK-001 Phase 3 Trial Fails To Achieve Primary Endpoint
07/18/16 09:03 AMEvoke Pharma's Phase 3 Clinical Trial Of EVK-001 Fails To Achieve Primary Endpoint
07/18/16 09:03 AMEvoke Pharma stock drops 76% after drug's late-stage topline results miss primary endpoint
07/18/16 09:03 AMEvoke Pharma Inc. (EVOK) Is Plunging After Phase 3 Study Failed
07/18/16 09:03 AMEVOKE PHARMA INC : Other Events (form 8-K)
07/17/16 08:26 AMStrong Sell Calls For Evoke Pharma, Inc. (NASDAQ:EVOK) At 0 - Investor Newswire
07/16/16 07:19 AMAnalyst Target and Average Rating Watch: Evoke Pharma, Inc. (NASDAQ:EVOK) - Press Telegraph
07/16/16 07:19 AMEvoke Pharma, Inc. (EVOK) Updated Price Targets - FTSE News

Social

About Evoke Pharma

Evoke Pharma logoEvoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EVOK
  • CUSIP:
Key Metrics:
  • Previous Close: $1.79
  • 50 Day Moving Average: $6.16
  • 200 Day Moving Average: $4.77
  • P/E Ratio: N/A
  • P/E Growth: -0.03
  • Market Cap: $11.80M
  • Beta: 1.18
  • Current Year EPS Consensus Estimate: $-1.43 EPS
  • Next Year EPS Consensus Estimate: $-1.1 EPS
Additional Links:
Evoke Pharma (NASDAQ:EVOK) Chart for Tuesday, July, 26, 2016